Written Question·Department of Health and Social Care·UIN 3568

Trastuzumab Deruxtecan

Tabled: 30 August 2024

Answered: 9 September 2024

Question

Rachel Gilmour

Liberal Democrat — Tiverton and Minehead

To ask the Secretary of State for Health and Social Care, if he will make representations to NICE on their decision to no longer offer Enertu for women suffering from metastatic HER2-LOW breast cancer.

Answer

Karin Smyth

Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of a treatment’s costs and benefits. NICE’s met...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 3568) →